Investigational Therapy Prolongs Survival in Rare Form of Acute Myeloid Leukemia

Article

Quizartinib has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia.

An investigational drug has prolonged survival for patients with acute myeloid leukemia (AML) who have a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD). The results of the phase 3 trial, which was led by The University of Texas MD Anderson Cancer Center, were presented at the European Hematology Society’s 23rd Congress.

AML with the FLT3-ITD mutation is a rare and deadly form of the disease that affects approximately one-third of patients with AML. These patients present with more aggressive disease and are more likely to relapse after remission.

So far, quizartinib, a second-generation FLT3 inhibitor, has shown promising activity. The new findings of the QUANTUM-R study presented at the European Hematology Society have confirmed the efficacy and safety of the treatment, as well as the value of targeting FLT3-ITD with the agent, which is a small molecule receptor tyrosine kinase inhibitor.

Click to continue reading on The American Journal of Managed Care.

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.